about
CSF tau and the CSF tau/ABeta ratio for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI)Plasma and Cerebrospinal fluid (CSF) Abeta42 for the differential diagnosis of Alzheimer's disease dementia in participants diagnosed with any dementia subtype in a specialist care settingPlasma and Cerebro Spinal Fluid Amyloid Beta 42, 40 and the 42:40 ratio for diagnosis of incipient Dementia in a population with objective cognitive declinePlasma and CSF Abeta for the longitudinal prediction of Alzheimer's disease dementia and other dementias in people with cognitive decline but no dementiaPlasma and Cerebro Spinal Fluid Amyloid Beta 42, 40 and the 42:40 ratio for diagnosis of incipient Dementia in a population with objective cognitive declineA review of clinical trial designs used to detect a disease-modifying effect of drug therapy in Alzheimer's disease and Parkinson's diseaseIncident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trialA systematic review of biomarkers for disease progression in Alzheimer's diseaseReporting standards for studies of diagnostic test accuracy in dementia: The STARDdem InitiativeEvaluation of exercise on individuals with dementia and their carers: a randomised controlled trial.Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial.Rapid restoration of cognition in Alzheimer's transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial Abeta.Dementia trials and dementia tribulations: methodological and analytical challenges in dementia research.Metal-protein attenuating compounds and Alzheimer's disease.Latest Advances on Interventions that May Prevent, Delay or Ameliorate Dementia.The PREVENT study: a prospective cohort study to identify mid-life biomarkers of late-onset Alzheimer's disease.Clinical practice with anti-dementia drugs: a consensus statement from British Association for Psychopharmacology.Ethical challenges in preclinical Alzheimer's disease observational studies and trials: Results of the Barcelona summit.ABT-126 monotherapy in mild-to-moderate Alzheimer's dementia: randomized double-blind, placebo and active controlled adaptive trial and open-label extension.Model-based economic evaluation in Alzheimer's disease: a review of the methods available to model Alzheimer's disease progression.An international perspective on advanced neuroimaging: cometh the hour or ivory tower?Health state values for use in the economic evaluation of treatments for Alzheimer's disease.The PREVENT research programme--a novel research programme to identify and manage midlife risk for dementia: the conceptual framework.Detecting cognitive changes in preclinical Alzheimer's disease: A review of its feasibility.Development of interventions for the secondary prevention of Alzheimer's dementia: the European Prevention of Alzheimer's Dementia (EPAD) project.CSF tau and the CSF tau/ABeta ratio for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).Recommended cognitive outcomes in preclinical Alzheimer's disease: Consensus statement from the European Prevention of Alzheimer's Dementia project.Change in Health-related Quality of Life After Referral to Memory Assessment Services.Is the effectiveness of memory assessment services associated with their structural and process characteristics?Alcohol and Alzheimer's Disease-Does Alcohol Dependence Contribute to Beta-Amyloid Deposition, Neuroinflammation and Neurodegeneration in Alzheimer's Disease?Establishing the motivations of patients with dementia and cognitive impairment and their carers in joining a dementia research register (DemReg).Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial.The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer's disease.A composite measure of cognitive and functional progression in Alzheimer's disease: Design of the Capturing Changes in Cognition study.PBT2 rapidly improves cognition in Alzheimer's Disease: additional phase II analyses.Prospective cohort studies in dementia.Metaanalysis of randomized trials of the efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer disease.Vascular risk factors and cognitive function among 3763 participants in the Hypertension in the Very Elderly Trial (HYVET): a cross-sectional analysis.Genetic variation in the alpha 7 nicotinic acetylcholine receptor is associated with delusional symptoms in Alzheimer's disease.A randomized, exploratory molecular imaging study targeting amyloid β with a novel 8-OH quinoline in Alzheimer's disease: The PBT2-204 IMAGINE study.
P50
Q24197654-3FD6111D-C95C-4634-8755-10CDEAFBEAB7Q24201276-73B0CC1E-E2BF-4BD4-91BD-1B5A2585BF9EQ24234762-A125D24A-1C27-49D2-8B87-56F43FFE1060Q24235058-439AEA41-AA7A-4768-A55C-AFC37B8E5590Q24236736-F208CE65-C8C8-40B6-959B-E94A028BD4DFQ27311651-2BC2D648-F274-4559-8A57-E588F61009EAQ28286628-8C99AC4E-A7DF-4B98-8EE9-9D0DE64E95D9Q28539868-DE36959E-CA80-47CC-876A-F301BB2BC951Q30585370-7CC4E15F-76FF-48E0-98E2-4FA859834CC0Q33898470-EEE40463-8628-48BA-8E15-3BB37032D754Q34283745-2401A0EB-AB5F-41F7-B034-D0C98FADF7A5Q34793942-C4FB547B-02E9-4B5A-B7A0-950479B2494FQ35189470-09FFD1F0-5871-4523-A019-891FA43D93FBQ35964717-EB5623B5-F1C7-44FB-A55A-C9F5ADC93D7EQ36443742-DAF54ED7-1457-4A3F-A02B-E42E2D0BD641Q36496436-ADBFB277-F289-483B-9BF4-1EE9C8F6B4BEQ36632771-E34FD384-4960-427E-AB0E-5704ED38FCA4Q36885357-D937C5CF-98DF-41FA-9562-9B0EA2DE4634Q37346136-62BD3699-05A0-49AD-9F2E-4E1D027D31F0Q37916856-E7ED67A2-619F-4693-87BB-F17F9F038EB8Q37917858-8803D490-4801-42DC-BD59-AB39FAAAF60EQ37970751-31905679-2EEB-4E3C-8CFA-47BDB85AD6F6Q38178375-A618CF96-667F-4124-8E4A-FF46215E0104Q38386875-01E1060C-F6C6-470A-B85F-B4368CBD21CBQ38673458-9BB29961-E406-4912-963E-7BE82288F801Q38741683-F917D55B-72F1-492A-A638-30D78779A7F4Q38814899-66AAE48E-84ED-4C5B-978D-9BF3BB86E644Q38935826-C49B16DB-F121-444D-99FD-568641E97E35Q38974253-A345B077-57BB-4FC3-96EB-16E31E95E3CCQ39028577-4107C31A-020B-4DB3-B095-E45DB5042F65Q39448572-A42CBD28-9B53-4F68-829A-004607824AFFQ40064054-9325DEE8-444A-40CA-A766-925E7D68A2BDQ42627792-BCB8CF54-1297-40D3-92DD-FC3B3E4E616BQ42656112-22BDD974-8E66-4E10-8FA7-F9E46C6D9C6AQ43158585-0E61E7D2-DB53-41E3-A531-BDA916659BA1Q44269408-EAB18FF8-6A22-44FE-B9AC-051149024E41Q44974957-552F8201-63FD-4516-8131-4C7B01BE6A1CQ46105396-B65ED935-4883-45B5-BF3C-FE5427BAD630Q46434067-429D31F8-31B4-4F89-864E-09B0A5572C29Q47145223-7A829334-398C-4043-83A8-C18FBF3A330E
P50
name
Craig W Ritchie
@ast
Craig W Ritchie
@en
Craig W Ritchie
@nl
type
label
Craig W Ritchie
@ast
Craig W Ritchie
@en
Craig W Ritchie
@nl
prefLabel
Craig W Ritchie
@ast
Craig W Ritchie
@en
Craig W Ritchie
@nl